Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Other financing activities (2016 - 2023)

Viking Therapeutics (VKTX) has disclosed Other financing activities for 8 consecutive years, with $37000.0 as the latest value for Q1 2023.

  • Quarterly Other financing activities changed N/A to $37000.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $56000.0 through Mar 2023, changed N/A year-over-year, with the annual reading at $22000.0 for FY2022, 52.17% down from the prior year.
  • Other financing activities hit $37000.0 in Q1 2023 for Viking Therapeutics, up from $19000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $37000.0 in Q1 2023 to a low of $7000.0 in Q4 2019.
  • Historically, Other financing activities has averaged $21000.0 across 3 years, with a median of $19000.0 in 2021.
  • Biggest YoY gain for Other financing activities was 97.53% in 2019; the steepest drop was 97.53% in 2019.
  • Year by year, Other financing activities stood at $7000.0 in 2019, then surged by 171.43% to $19000.0 in 2021, then soared by 94.74% to $37000.0 in 2023.
  • Business Quant data shows Other financing activities for VKTX at $37000.0 in Q1 2023, $19000.0 in Q4 2021, and $7000.0 in Q4 2019.